Recent advances in neurobiology of Tuberous Sclerosis Complex

Valerio Napolioni, Romina Moavero, Paolo Curatolo

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder with variable phenotypic expression, due to a mutation in one of the two genes, TSC1 and TSC2, and a subsequent hyperactivation of the downstream mTOR pathway, resulting in increased cell growth and proliferation. The central nervous system is consistently involved in TSC, with 90% of individuals affected showing structural abnormalities, and almost all having some degree of CNS clinical manifestations, including seizures, cognitive impairment and behavioural problems. TSC is proving to be a particularly informative model for studying contemporary issues in developmental neurosciences. Recent advances in the neurobiology of TSC from molecular biology, molecular genetics, and animal model studies provide a better understanding of the pathogenesis of TSC-related neurological symptoms. Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.

Original languageEnglish
Pages (from-to)104-113
Number of pages10
JournalBrain and Development
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Tuberous Sclerosis
Neurobiology
Sirolimus
Molecular Biology
Inborn Genetic Diseases
Molecular Models
Genetic Models
Brain Diseases
Neurosciences
Seizures
Central Nervous System
Animal Models
Cell Proliferation
Clinical Trials
Mutation
Growth
Genes

Keywords

  • Autism
  • Epilepsy
  • Mental retardation
  • mTOR
  • Rapamycin
  • TSC1
  • TSC2
  • Tuberous sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Pediatrics, Perinatology, and Child Health

Cite this

Recent advances in neurobiology of Tuberous Sclerosis Complex. / Napolioni, Valerio; Moavero, Romina; Curatolo, Paolo.

In: Brain and Development, Vol. 31, No. 2, 02.2009, p. 104-113.

Research output: Contribution to journalArticle

Napolioni, Valerio ; Moavero, Romina ; Curatolo, Paolo. / Recent advances in neurobiology of Tuberous Sclerosis Complex. In: Brain and Development. 2009 ; Vol. 31, No. 2. pp. 104-113.
@article{699b58fe6ca3490b8802d1dfa1a185c4,
title = "Recent advances in neurobiology of Tuberous Sclerosis Complex",
abstract = "Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder with variable phenotypic expression, due to a mutation in one of the two genes, TSC1 and TSC2, and a subsequent hyperactivation of the downstream mTOR pathway, resulting in increased cell growth and proliferation. The central nervous system is consistently involved in TSC, with 90{\%} of individuals affected showing structural abnormalities, and almost all having some degree of CNS clinical manifestations, including seizures, cognitive impairment and behavioural problems. TSC is proving to be a particularly informative model for studying contemporary issues in developmental neurosciences. Recent advances in the neurobiology of TSC from molecular biology, molecular genetics, and animal model studies provide a better understanding of the pathogenesis of TSC-related neurological symptoms. Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.",
keywords = "Autism, Epilepsy, Mental retardation, mTOR, Rapamycin, TSC1, TSC2, Tuberous sclerosis",
author = "Valerio Napolioni and Romina Moavero and Paolo Curatolo",
year = "2009",
month = "2",
doi = "10.1016/j.braindev.2008.09.013",
language = "English",
volume = "31",
pages = "104--113",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Recent advances in neurobiology of Tuberous Sclerosis Complex

AU - Napolioni, Valerio

AU - Moavero, Romina

AU - Curatolo, Paolo

PY - 2009/2

Y1 - 2009/2

N2 - Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder with variable phenotypic expression, due to a mutation in one of the two genes, TSC1 and TSC2, and a subsequent hyperactivation of the downstream mTOR pathway, resulting in increased cell growth and proliferation. The central nervous system is consistently involved in TSC, with 90% of individuals affected showing structural abnormalities, and almost all having some degree of CNS clinical manifestations, including seizures, cognitive impairment and behavioural problems. TSC is proving to be a particularly informative model for studying contemporary issues in developmental neurosciences. Recent advances in the neurobiology of TSC from molecular biology, molecular genetics, and animal model studies provide a better understanding of the pathogenesis of TSC-related neurological symptoms. Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.

AB - Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder with variable phenotypic expression, due to a mutation in one of the two genes, TSC1 and TSC2, and a subsequent hyperactivation of the downstream mTOR pathway, resulting in increased cell growth and proliferation. The central nervous system is consistently involved in TSC, with 90% of individuals affected showing structural abnormalities, and almost all having some degree of CNS clinical manifestations, including seizures, cognitive impairment and behavioural problems. TSC is proving to be a particularly informative model for studying contemporary issues in developmental neurosciences. Recent advances in the neurobiology of TSC from molecular biology, molecular genetics, and animal model studies provide a better understanding of the pathogenesis of TSC-related neurological symptoms. Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.

KW - Autism

KW - Epilepsy

KW - Mental retardation

KW - mTOR

KW - Rapamycin

KW - TSC1

KW - TSC2

KW - Tuberous sclerosis

UR - http://www.scopus.com/inward/record.url?scp=58249127284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249127284&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2008.09.013

DO - 10.1016/j.braindev.2008.09.013

M3 - Article

VL - 31

SP - 104

EP - 113

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 2

ER -